Efalizumab-induced severe thrombocytopenia can be resolved

Francesca Prignano, F Zanieri, S Mokhtarzadeh, T LottiUniversity Unit of Dermatology and Physiotherapy, School of Medicine, University of Florence, Florence, ItalyAbstract: Efalizumab is a monoclonal a humanized recombinant IgG1 monoclonal antibody which targets the CD11a, the alpha-subunit of LFA-1...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Francesca Prignano, F Zanieri, S Mokhtarzadeh, T Lotti
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2008
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/0c08f4768c4943ccba5044ea7fd8453e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0c08f4768c4943ccba5044ea7fd8453e
record_format	dspace
spelling	oai:doaj.org-article:0c08f4768c4943ccba5044ea7fd8453e2021-12-02T06:00:06ZEfalizumab-induced severe thrombocytopenia can be resolved1177-54751177-5491https://doaj.org/article/0c08f4768c4943ccba5044ea7fd8453e2008-11-01T00:00:00Zhttp://www.dovepress.com/efalizumab-induced-severe-thrombocytopenia-can-be-resolved-a2546https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Francesca Prignano, F Zanieri, S Mokhtarzadeh, T LottiUniversity Unit of Dermatology and Physiotherapy, School of Medicine, University of Florence, Florence, ItalyAbstract: Efalizumab is a monoclonal a humanized recombinant IgG1 monoclonal antibody which targets the CD11a, the alpha-subunit of LFA-1 (lymphocyte function-associated antigen-1). It acts by blocking the T-lymphocyte pathogenetic mechanisms of psoriasis. Thrombocytopenia is an adverse event that occurs during therapy. Thrombocytopenia can be mild and can occur quite early during treatment, together with leukocytosis. Both adverse events tend to normalize with ongoing therapy, or, in cases worsening, with therapy suspension. There have been multiple reports of thrombocytopenia associated with efalizumab therapy for the treatment of psoriasis. The general recommendation is to check platelet counts monthly for the first 3 months of efalizumab therapy, then every 3 months for the duration of therapy. According to our experience on a wide range of patients, it is useful to check platelets every month for the first 6 months of therapy. We report a case of efalizumab-associated thrombocytopenia that occurred after 16 weeks of therapy together with clinical worsening of skin lesions. The peculiarity of our case is the absence of signs and symptoms linked to thrombocytopenia and the quick return to normal platelet count without corticosteroid therapy.Keywords: efalizumab, thrombocytopenia, psoriasis Francesca PrignanoF ZanieriS MokhtarzadehT LottiDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2008, Iss Issue 4, Pp 923-927 (2008)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Francesca Prignano F Zanieri S Mokhtarzadeh T Lotti Efalizumab-induced severe thrombocytopenia can be resolved
description	Francesca Prignano, F Zanieri, S Mokhtarzadeh, T LottiUniversity Unit of Dermatology and Physiotherapy, School of Medicine, University of Florence, Florence, ItalyAbstract: Efalizumab is a monoclonal a humanized recombinant IgG1 monoclonal antibody which targets the CD11a, the alpha-subunit of LFA-1 (lymphocyte function-associated antigen-1). It acts by blocking the T-lymphocyte pathogenetic mechanisms of psoriasis. Thrombocytopenia is an adverse event that occurs during therapy. Thrombocytopenia can be mild and can occur quite early during treatment, together with leukocytosis. Both adverse events tend to normalize with ongoing therapy, or, in cases worsening, with therapy suspension. There have been multiple reports of thrombocytopenia associated with efalizumab therapy for the treatment of psoriasis. The general recommendation is to check platelet counts monthly for the first 3 months of efalizumab therapy, then every 3 months for the duration of therapy. According to our experience on a wide range of patients, it is useful to check platelets every month for the first 6 months of therapy. We report a case of efalizumab-associated thrombocytopenia that occurred after 16 weeks of therapy together with clinical worsening of skin lesions. The peculiarity of our case is the absence of signs and symptoms linked to thrombocytopenia and the quick return to normal platelet count without corticosteroid therapy.Keywords: efalizumab, thrombocytopenia, psoriasis
format	article
author	Francesca Prignano F Zanieri S Mokhtarzadeh T Lotti
author_facet	Francesca Prignano F Zanieri S Mokhtarzadeh T Lotti
author_sort	Francesca Prignano
title	Efalizumab-induced severe thrombocytopenia can be resolved
title_short	Efalizumab-induced severe thrombocytopenia can be resolved
title_full	Efalizumab-induced severe thrombocytopenia can be resolved
title_fullStr	Efalizumab-induced severe thrombocytopenia can be resolved
title_full_unstemmed	Efalizumab-induced severe thrombocytopenia can be resolved
title_sort	efalizumab-induced severe thrombocytopenia can be resolved
publisher	Dove Medical Press
publishDate	2008
url	https://doaj.org/article/0c08f4768c4943ccba5044ea7fd8453e
work_keys_str_mv	AT francescaprignano efalizumabinducedseverethrombocytopeniacanberesolved AT fzanieri efalizumabinducedseverethrombocytopeniacanberesolved AT smokhtarzadeh efalizumabinducedseverethrombocytopeniacanberesolved AT tlotti efalizumabinducedseverethrombocytopeniacanberesolved
_version_	1718400092435644416

Efalizumab-induced severe thrombocytopenia can be resolved

Ejemplares similares